BCB
ALNY icon

Brian C. Broderick’s Alnylam Pharmaceuticals ALNY Stock Holding History

Brian C. Broderick’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,849
Closed -$219K – 93
2016
Q4 		$219K Sell
5,849
-20
-0.3% -$837 0.09% 90
2016
Q3 		$398K Sell
5,869
-113
-2% -$7.97K 0.17% 78
2016
Q2 		$331K Buy
5,982
+1,010
+20% +$63.6K 0.14% 84
2016
Q1 		$313K Buy
4,972
+47
+1% +$3.13K 0.14% 87
2015
Q4 		$464K Buy
4,925
+40
+0.8% +$3.71K 0.21% 75
2015
Q3 		$393K Sell
4,885
-102
-2% -$11.3K 0.18% 76
2015
Q2 		$597K Sell
4,987
-40
-0.8% -$4.78K 0.25% 69
2015
Q1 		$525K Buy
5,027
+325
+7% +$32.9K 0.22% 71
2014
Q4 		$457K Sell
4,702
-151
-3% -$14K 0.19% 74
2014
Q3 		$380K Sell
4,853
-25
-0.5% -$1.61K 0.17% 79
2014
Q2 		$309K Buy
4,878
+120
+3% +$7.13K 0.14% 84
2014
Q1 		$320K Sell
4,758
-4,662
-49% -$361K 0.16% 77
2013
Q4 		$606K Sell
9,420
-235
-2% -$14K 0.3% 65
2013
Q3 		$618K Sell
9,655
-275
-3% -$13.7K 0.34% 63
2013
Q2 		$308K Buy
+9,930
New +$264K 0.18% 76

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Brian C. Broderick's ALNY Position: Q1 2017 in Review

Brian C. Broderick sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2017, closing a stake of 5,849 shares — an estimated $219K sold.

Brian C. Broderick first reported a position in ALNY in Q2 2013 and held it in 15 quarters. The position peaked at $618K in Q3 2013. 199 funds tracked by Wall St. Rank hold ALNY as of Q1 2017.

  • Brian C. Broderick reported no remaining Alnylam Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Brian C. Broderick sold 5,849 Alnylam Pharmaceuticals shares in Q1 2017, an estimated $219K.
  • Brian C. Broderick first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 15 quarters.
  • Brian C. Broderick's Alnylam Pharmaceuticals position peaked at $618K in Q3 2013.
  • 199 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2017.

Based on Brian C. Broderick's 13F filing for Q1 2017, filed 16 May 2017.